Laboratory Monitoring of Direct Oral Anticoagulants (Doacs)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Extended-Duration Betrixaban Versus Shorter-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Critically Ill Medical
Intensive Care Med (2019) 45:477–487 https://doi.org/10.1007/s00134-019-05565-6 ORIGINAL Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy Gerald Chi1* , C. Michael Gibson2, Arzu Kalayci1, Alexander T. Cohen3, Adrian F. Hernandez4, Russell D. Hull5, Farima Kahe1, Mehrian Jafarizade1, Sadaf Sharfaei1, Yuyin Liu6, Robert A. Harrington7 and Samuel Z. Goldhaber8 © 2019 Springer-Verlag GmbH Germany, part of Springer Nature Abstract Purpose: To assess the efcacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among criti- cally ill patients. Methods: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35–42 days or enoxa- parin for 10 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and± 547 patients who had no severe renal insufciency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical beneft (composite of VTE and major bleeding), and mortality was compared at 35–42 days and at 77 days. Results: At 35–42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P 0.042) without causing excess major bleeding (1.14% vs 3.13%, P 0.07). Both VTE (3.32% vs 8.33%, P 0.013) and= major bleeding (0.00% vs 3.26%, P 0.003) were decreased in the full-dose= stratum. Patients who received= betrixaban had more non-major bleeding= than enoxaparin (overall population: 2.56% vs 0.28%, P 0.011; full-dose stratum: 3.32% vs 0.36%, P 0.010). -
Standard-Dose Apixaban After Very Low-Dose Thrombolysis for Acute Intermediate-High Risk Acute Pulmonary Embolism
SAFE-LYSE | STUDY PROTOCOL Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis Title: for Acute Intermediate-high Risk Acute Pulmonary Embolism Short Title: SAFE-LYSE Protocol Version: Issue Date: 28/AUG/2019 Principal Victor Tapson1,2, Aaron Weinberg1,2 Investigators: Sub Investigators: Sam Torbati1, Susan Jackman1, Niree Hindoyan1, Joseph Meza1 1Cedars-Sinai Medical Center 8700 Beverly Blvd Los Angeles, CA 90048 Affiliations: 2Cedars-Sinai Medical GrouP 200 N. Robertson Blvd. Beverly Hills, CA 90211 Victor TaPson 8730 Alden Drive, W155 Primary Contact: Los Angeles, CA 90048 (919) 971-6441 Investigator-Initiated Bristol-Myers Squibb Company (BMS) Study Funded By: Version 8.0 | Date: 28Aug2019 1 SAFE-LYSE | STUDY PROTOCOL STUDY SYNOPSIS Funding Provided by BMS/Pfizer Alliance Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Protocol Title Acute Intermediate-high Risk Acute Pulmonary Embolism (SAFE-LYSE) Pulmonary embolism (PE) is a major cause of mortality in the United States, with an estimated 100,000 deaths annually and uP to 30% of Patients dying within the first month of diagnosis. Recent guidelines now risk-stratify intermediate-risk PE Patients to intermediate-low and intermediate-high risk categories, but consensus on treatment for those Patients are controversial, as compared to that of high or low-risk Patients. Because of an increased risk of major, non-major, and intracranial bleeding and an uncertain effect on survival and Post-thrombotic complications, thrombolysis is not routinely recommended in the guidelines for intermediate- risk Patients. However, studies have evaluated half-dose (50 mg dose) tissue Plasminogen activator (tPA) and this aPPears to be effective for treating PE with a reduced yet still significant risk of bleeding. -
Doacs) and the Antidote Idarucizumab
Update overview 2019 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2018) in consultation with the Medicines Evaluation Board CBG-MEB, concerning the direct oral anticoagulants (DOACs) dabigatran Pradaxa®, registered in the Netherlands in 2008 [1], rivaroxaban Xarelto®, registered in 2008 [2], apixaban Eliquis®, registered in 2011 [3] and edoxaban (Lixiana®), registered in 2015 [4-9]. The current overview provides a new yearly update of the reports received by Lareb for these DOACs. Furthermore, reports received by Lareb for the antidote idarucizumab are described in this overview. Idarucizumab is a specific antidote for dabigatran and was registered in the Netherlands in 2015 [10]. For this overview, data from the national ADR database were used. These data include reports with serious outcome from the Lareb Intensive Monitoring System (LIM). The DOACs have been monitored with the LIM methodology since September 2012. Prescription data The number of patients using DOACs in the Netherlands according to the GIP database is shown in table 1 [11]. These data are based on extramurally provided medication included in the Dutch health insurance package. Because the antidote idarucizumab is administered in the hospital and not reimbursed directly via the healthcare insurance, these data are not available for this drug. The number of reports received by the Netherlands Pharmacovigilance Centre Lareb per year since 2013 for each DOAC, is also shown in table 1. Furthermore, table 1 shows the calculated number of these reports per 1.000 users according to the GIP database. As noted before, the data from the GIP database represent reimbursed medicines and these may differ from actually prescribed medicines. -
Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults With
CLINICAL INVESTIGATION Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan Chao-Lun Lai, MD, PhD,*†‡§ Ho-Min Chen, MS,† Min-Tsun Liao, MD,* and Ting-Tse Lin, MD* mortality and cardiovascular mortality than those who OBJECTIVES: To compare the effectiveness and safety of used warfarin. Reduced-dose dabigatran was also associ- reduced-dose dabigatran, reduced-dose rivaroxaban, and warfa- ated with lower risk of intracranial hemorrhage than war- rin in individuals aged 85 and older with atrial fibrillation (AF). farin. J Am AmGeriatr GeriatrSoc Soc66:1567–1574, 2018. 2018. DESIGN: Retrospective cohort study. SETTING: Taiwan National Health Insurance claims database, 20112015. Key words: dabigatran; rivaroxaban; warfarin; effec- PARTICIPANTS: Individuals with AF aged 85 and older tiveness; safety; octogenarian (mean 88.6) with incident use of oral anticoagulants between June 1, 2012 and May 31, 2015 (N54,722; dabi- gatran 110 mg, n51,489; rivaroxaban 15 mg/10 mg, n51,736; warfarin, n51,497). MEASUREMENTS: Clinical outcomes included all-cause death, cardiovascular death, ischemic stroke, acute myocardial he risk of ischemic stroke is 5 times as high in individ- infarction, arterial embolism or thrombosis, intracranial hem- T uals with atrial fibrillation (AF) than in those with- orrhage, and gastrointestinal hemorrhage needing transfusion. out.1 Warfarin, the classic vitamin K antagonist, can reduce 2 Propensity score–matched analysis was performed, and the the risk of ischemic stroke by approximately 60%, but the marginal proportional hazards model was used to estimate the narrow therapeutic window and risk of bleeding complica- relative risk of various clinical outcomes in a matched tions associated with warfarin therapy have led to its being 1 dabigatran-warfarin cohort (n51,180 in each group) and a underused. -
Edoxaban Switch Programme - Frequently Asked Questions
Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in NV-AF(non-valvular atrial fibrillation) Edoxaban has been identified as the first choice DOAC. It is similarly effective to the other DOAC options but costs considerably less Clinical experts in Tayside are supporting the use of edoxaban All newly diagnosed NV-AF patients will be started on edoxaban as 1st choice for those unsuitable for warfarin Existing patients already on a DOAC for NV-AF are to be reviewed and considered for switch to edoxaban This will help to ensure that the money available to spend on medicines is being used appropriately Is edoxaban as good as the other DOACs? Yes, the evidence is that it is as effective as warfarin and the other DOACs. It is licensed for this indication and has been recommended by the Scottish Medicines Consortium Other Scottish Health Boards are also considering the use of edoxaban A recent Health Improvement Scotland (HIS) summary (http://www.healthcareimprovementscotland.org/our_work/cardiovascular_dis ease/programme_resources/doac_review_report.aspx) is consistent with this Tayside switch recommendation Lead clinicians from cardiology, stroke, vascular medicine, relevant MCN’s and haematology are all supportive of this Tayside guidance on the basis of current evidence Will we need to do a further switch if the price of other DOACs falls? The rebate on edoxaban is in place for five -
DOACS COMPARISON and Faqs
NOACS/DOACS*: PRACTICAL ISSUES AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: • To summarize characteristics of the direct oral anticoagulants (DOACs) currently available in Canada. • To address common practical issues related to DOAC use. • To address frequently asked questions regarding DOACs. BACKGROUND: The DOACs, which consist of apixaban, dabigatran, edoxaban, and rivaroxaban are used for the prevention and treatment of venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). Practical advantages of DOACs over warfarin include fixed once- or twice-daily oral dosing without the need for coagulation test monitoring, relatively fewer known drug interactions and no known food interactions. Like warfarin, DOACs increase the risk for bleeding and should be administered under close clinical monitoring. Practical issues regarding the everyday use of DOACs will be addressed in this guide. PRACTICAL AND LIFESTYLE ISSUES: Can DOACs be taken with meals? Rivaroxaban should be taken with meals to enhance absorption; the tablet can be crushed and taken with soft foods such as applesauce. Apixaban, dabigatran, edoxaban can be taken with or without meals. However, taking dabigatran with meals can reduce dyspepsia. Dabigatran capsules should not be opened, broken or chewed before swallowing. Are there any foods or beverages that need to be avoided with DOACs? Unlike with warfarin, there are no known food interactions with DOACs, so there are no food restrictions when taking these medications. In addition, there is no evidence that drinking grapefruit juice affects the effectiveness or safety of DOACs. In general, it is acceptable for patients taking a DOAC to drink alcoholic beverages in moderation (e.g. a glass of wine with a meal) as it is for patients on warfarin. -
Anatomisch-Therapeutisch-Chemische Klassifikation Mit Tagesdosen Für Den Deutschen Arzneimittelmarkt Gemäß § 73 Abs
Wissenschaftliches Institut der AOK GKV-Arzneimittelindex Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt gemäß § 73 Abs. 8 Satz 5 SGB V. 14. Sitzung der Arbeitsgruppe ATC/DDD des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen am 27. November 2015, BMG in Berlin © WIdO 2015 GKV-Arzneimittelindex Agenda • Das anatomisch-therapeutisch-chemische Klassifikationssystem • Entwicklung der ATC/DDD Klassifikation • Workflow ATC/DDD 2016 • Beschlussvorlage • Stellungnahmen zu der Beschlussvorlage • Workflow ATC/DDD 2017 © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 2 GKV-Arzneimittelindex Agenda • Das anatomisch-therapeutisch-chemische Klassifikationssystem • Entwicklung der ATC/DDD Klassifikation • Workflow ATC/DDD 2016 • Beschlussvorlage • Stellungnahmen zu der Beschlussvorlage • Workflow ATC/DDD 2017 © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 3 GKV-Arzneimittelindex Das Anatomisch-therapeutisch-chemische Klassifikationssystem A Alimentäres System und Stoffwechsel B Blut und blutbildende Organe C Kardiovaskuläres System D Dermatika G Urogenitalsystem und Sexualhormone H Systemische Hormonpräparate, exkl. Sexualhormone u. Insuline J Antiinfektiva zur systemischen Anwendung L Antineoplastische und immunmodulierende Mittel M Muskel- und Skelettsystem N Nervensystem P Antiparasitäre Mittel, Insektizide und Repellenzien R Respirationstrakt S Sinnesorgane V Varia © WIdO 2015 14. Sitzung der Arbeitsgruppe ATC/DDD des KKG 4 GKV-Arzneimittelindex Das Anatomisch-therapeutisch-chemische -
Atrial Fibrillation
CONFIDENTIAL NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Premeeting briefing Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation This briefing presents the key issues arising from the manufacturer’s submission, Evidence Review Group (ERG) report and statements made by consultees and their nominated clinical specialists and patient experts. Please note that this briefing is a summary of the information available and should be read with the full supporting documents. The manufacturer was asked to…. provide justification for reducing the dabigatran treatment dose from 150 mg to 110 mg at 80 years of age comment on the impact of being unable to utilise P-glycoprotein inhibitors on the use of dabigatran and the management of atrial fibrillation provide a justification for choosing the mixed treatment comparison (MTC) (SAS) for the base case instead of the results from the MTC (WinBUGs) provide a comparison of the different hazard ratios from the MTC (SAS), MTC (WinBUGS) analyses and the direct pairwise results and justify any discrepancies justify the exclusion of trials with zero event arms from the MTC provide a revised model with the ability to choose any of the included treatments (dabigatran or warfarin) as either a first-line or a second-line treatment option provide base-case cost-effectiveness results comparing dabigatran 110 mg and 150 mg when used as either first-line treatment or as a second-line treatment following warfarin analyse and provide base-case cost-effectiveness comparing the results of the following treatment sequences: dabigatran → warfarin → aspirin → no treatment and warfarin → aspirin → no treatment. -
Lixiana, INN-Edoxaban
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Lixiana 15 mg film-coated tablets Lixiana 30 mg film-coated tablets Lixiana 60 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Lixiana 15 mg film-coated tablets Each 15 mg film-coated tablet contains 15 mg edoxaban (as tosilate). Lixiana 30 mg film-coated tablets Each 30 mg film-coated tablet contains 30 mg edoxaban (as tosilate). Lixiana 60 mg film-coated tablets Each 60 mg film-coated tablet contains 60 mg edoxaban (as tosilate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Lixiana 15 mg film-coated tablets Orange, round-shaped film-coated tablets (6.7 mm diameter) debossed with “DSC L15”. Lixiana 30 mg film-coated tablets Pink, round-shaped film-coated tablets (8.5 mm diameter) debossed with “DSC L30”. Lixiana 60 mg film-coated tablets Yellow, round-shaped film-coated tablets (10.5 mm diameter) debossed with “DSC L60”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Lixiana is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Lixiana is indicated in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). 2 4.2 Posology and method of administration Posology Prevention of stroke and systemic embolism The recommended dose is 60 mg edoxaban once daily. -
Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate) Savaysa (Edoxaban) Xarelto 2.5Mg (Rivaroxaban) Effective 01/01/2021
Anticoagulant Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban) Xarelto 2.5mg (rivaroxaban) Effective 01/01/2021 ☒ MassHealth Plan ☒ ☐Commercial/Exchange Prior Authorization Program Type ☒ Quantity Limit ☒ Pharmacy Benefit Benefit ☐ Step Therapy ☐ Medical Benefit (NLX) Specialty N/A Limitations Specialty Medications All Plans Phone: 866-814-5506 Fax: 866-249-6155 Non-Specialty Medications Contact MassHealth Phone: 877-433-7643 Fax: 866-255-7569 Information Commercial Phone: 800-294-5979 Fax: 888-836-0730 Exchange Phone: 855-582-2022 Fax: 855-245-2134 Medical Specialty Medications (NLX) All Plans Phone: 844-345-2803 Fax: 844-851-0882 Exceptions N/A Overview Xarelto and Savaysa are factor Xa inhibitors which inhibit platelet activation and fibrin clot formation. Pradaxa is a thrombin inhibitor which blocks free and fibrin bound thrombin. These medications are indicated for: . Treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) – Pradaxa and Savaysa . Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. – Pradaxa, Xarelto, and Savaysa . Prophylaxis of DVT and/or PE in patients who have undergone total hip arthroplasty. - Xarelto and Pradaxa . Prophylaxis of venous thromboembolism (VTE) – Xarelto . Reduction in the risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE) – Xarelto . Reduction of risk of major cardiovascular (CV) events (CV death, myocardial infarction, and stroke) in patients with coronary artery disease (chronic) or peripheral artery disease. - Xarelto No PA PA required Pradaxa® (dabigatran etexilate mesylate 110 mg) ≤ 70 Pradaxa® (dabigatran etexilate mesylate 75 mg, 150 capsules/365 days mg) Pradaxa® (dabigatran etexilate mesylate 110 mg) > 70 Eliquis® (apixaban) PD capsules/365 days ® ® Xarelto (rivaroxaban 10 mg, 15 mg, 20 mg, starter pack) Savaysa (edoxaban) ® Xarelto (rivaroxaban 2.5 mg tablet) PD Preferred Drug. -
Transition of Anticoagulants 2019
Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran, -
BIOPHEN™ Heparin LRT Assay Can Be Calibrated for the Assay of Various Anti-Xa Anti-Xa Drugs Are Absent from Normal Plasma
BIOPHEN™ Heparin LRT REF 221011 R1 R2 4 x 7.5 mL REF 221013 R1 R2 3 x 3 mL Sales and Support: CoaChrom Diagnostica GmbH REF 221015 R1 R2 4 x 5 mL www.coachrom.com | [email protected] Tel: +43-1-236 222 1 | Fax: +43-1-236 222 111 Toll-free contact for Germany: Tel: 0800-24 66 33-0 | Fax: 0800-24 66 33-3 Anti-Xa chromogenic method for the assay of Heparin and their analogs, and direct FXa inhibitors, with ready to use liquid reagents English, last revision: 04-2019 INTENDED USE: For manual method, allow to stabilize for 30 minutes at room temperature (18-25°C), The BIOPHEN™ Heparin LRT kit is an anti-Xa chromogenic method for the in vitro homogenize before use. quantitative determination of heparin and theirs analogs, in human citrated plasma, using a manual or automated method. This method is appropriate for the Apixaban, STORAGE AND STABILITY: Rivaroxaban and Edoxaban assay, direct Factor Xa (FXa) inhibitors. This method is Unopened reagents should be stored at 2-8°C in their original packaging. Under these also appropriate for the determination of anti-Xa activity assay of Arixtra® conditions, they can be used until the expiry date printed on the kit. (Fondaparinux) and Orgaran® (Sodium Danaparoïd), indirect inhibitors whose activity is mediated by plasma antithrombin (AT). Reagents are in the liquid presentation, ready R1 R2 Reagent stability after opening, free from any contamination or evaporation, to use (LRT, Liquid reagent Technology). and stored closed, is of: ▪ 6 months at 2-8°C.